PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportst-cell lymphoma peripheral
MeSH D016411 - t-cell lymphoma peripheral
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D016399:T-cell lymphoma
0 Companies
0 Drugs
Success rate
D016411: 
T-cell lymphoma peripheral
4 Companies
3 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Acrotech BiopharmaBelinostat Beleodaq 2026-08-10 2014-07-03   
Pralatrexate Folotyn 2022-07-16 2009-09-24   
Bristol Myers SquibbRomidepsin Istodax  2009-11-05   
Fresenius KabiRomidepsin Romidepsin  2021-10-12   
TevaRomidepsin Romidepsin  2020-03-13   
Clinical Trials
Historical Success Rate
Phase 1
72%
67/93
Phase 2
24%
22/93
Phase 3
29%
7/24
Approved: 3Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Acrotech Biopharma
Belinostat,
Pralatrexate,
Ademetionine,
Methylcobalamin,
Sodium chloride,
Retinol,
Caelyx,
Doxorubin,
Hydroxydaunomycin
Bristol Myers Squibb
Romidepsin,
Cilmostim,
Imgatuzumab,
Sodium lactate,
CABIRALIZUMAB,
Microcrystalline cellulose,
Caelyx,
Doxorubin,
Vp16,
Solumedrol,
Hydroxydaunomycin,
Evidence
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use